Looking at the course of developments — in the healthcare reform "debate" (as it were) and medical technology — it is not a huge leap of judgment to make the following predictions for the ups and downs of healthcare overall and for specific medical technologies. Predictions for the healthcare market A healthcare reform package will [...]
A meta-analysis by the Cardiovascular Research Foundation, and published in the June 15 edition of Circulation, of 56 studies that covered 190,000 patients revealed unambiguous benefits for use of drug-eluting stents (DES) instead of bare metal stents. DES resulted in a reduction in death from no difference (meta-analysis of 22 randomized trials) to a 22% reduction [...]
In spite of arguments contesting whether bare metal or drug-eluting stents perform better, drug-eluting stents are here to stay and are still used in the majority of stent implantations. In fact, a plethora of studies have shown that DES can improve mortality rates and reduce the need for target vessel revascularization (TVR) compared with BMS. [...]
This is one of the largest clinical trials comparing PCI (with DES) with CABG. Results presented at TCT 2008 found no significant difference in treatment outcomes of patients who were stented compared with those who underwent coronary artery bypass grafting. Also at TCT 2008, Boston Scientific’s next-generation Liberte stent was shown to have high marks [...]
In addition to bare metal, drug-eluting and absorbable stents on the market or under development for the treatment of coronary artery diseases, innovative companies have developed other types of stents to treat cardiovascular disease. These include bioactive coatings, antibody coatings, biomimetic coatings, hydrophilic coatings, titanium-nitride-oxide coatings, pericardium-covered stents, radioactive stents, synthetic graft alternatives, tissue engineered coatings, stents [...]
Angioplasty for the revascularization of blocked coronary arteries gave way in the evolution of clinical practice to the adjunctive use of bare metal coronary stents, but due to a high frequency of restenosis bare metal stents gave way to drug-eluting stents (DESs) in 2003 (J&J/CYPHER, followed in 2004 by Boston Scientific’s TAXUS, and soon followed by [...]
Cardiovascular disease includes high blood pressure, coronary heart disease (myocardial infarction, angina pectoris), heart failure, stroke, and congenital cardiovascular defects. Roughly 80 million Americans have one or more of these types of heart disease. Of those, more than 38 million are greater than 60 years of age. Cardiovascular disease is the leading cause of death [...]
The global market for drug-eluting, bare and bioresorbable stents for the treatment of coronary artery disease is in a "growth and proliferation" phase, as the market for these devices is growing steadily through application to growing patient caseload, and as the number of companies with approved products or products in development multiplies. The bulk of interest [...]
Lest anyone believe that drug-eluting coronary stents have taken over the acute myocardial infarction world, a good number of companies are active in the development and marketing of bare metal stents. See a list of manufacturers below, drawn from the MedMarket Diligence Report #C245, "Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017." Aachen [...]
There is a wide range of clinical trials evaluating drug-eluting, bare, and resorbable coronary stents for their safety, efficacy and performance. Below are many of the key trials in process or completed. ABSORB HORIZONS-AMI ARRIVE II Registry ISAR, ISAR-TEST-2 ARTS LONG DES AXXESS PLUS NOBLESS BASKET NOBORI BBC ONE NORDIC CARE OLYMPIA Registry COREL [...]
Contact:
